Abstract
Osteoarthritis is usually regarded as a localized disease whose optimal treatment is a therapy applied directly to the affected joint. Unfortunately, current local therapies such as repeated intraarticular injections or constant infusions are associated with a higher risk of infection. One way to overcome this would be to transfer substances made locally by cells within the joint. However, attempts using direct vector transfers or intraarticular injections of ex vivo modified cells could not achieve a sustained protein secretion over several months. Another method of delivering biological factors (i.e.growth hormones) intraarticularly is to transplant an artificial organ, capable of supporting the regeneration of natural cartilage, directly into the affected joint The main difficulty of having to produce bioactive factors over a long period of time is overcome by implanting a chamber-like system filled with either genetically modified cells or a drug-releasing matrix. This drug delivery system would be located at a peripheral site of the joint and could release substances directly into the joint cavity which would be transported via the synovial fluid and/or diffused to the chondrocytes or synoviocytes.
Keywords: Cartilage, osteoarthritis, therapy, drug delivery, artificial organ
Current Drug Delivery
Title: Artificial Organs: A New Option for Treating Osteoarthritis
Volume: 4 Issue: 1
Author(s): J. Stove, L. Lehmann, S. Fickert, T. Aigner and R. Brenner
Affiliation:
Keywords: Cartilage, osteoarthritis, therapy, drug delivery, artificial organ
Abstract: Osteoarthritis is usually regarded as a localized disease whose optimal treatment is a therapy applied directly to the affected joint. Unfortunately, current local therapies such as repeated intraarticular injections or constant infusions are associated with a higher risk of infection. One way to overcome this would be to transfer substances made locally by cells within the joint. However, attempts using direct vector transfers or intraarticular injections of ex vivo modified cells could not achieve a sustained protein secretion over several months. Another method of delivering biological factors (i.e.growth hormones) intraarticularly is to transplant an artificial organ, capable of supporting the regeneration of natural cartilage, directly into the affected joint The main difficulty of having to produce bioactive factors over a long period of time is overcome by implanting a chamber-like system filled with either genetically modified cells or a drug-releasing matrix. This drug delivery system would be located at a peripheral site of the joint and could release substances directly into the joint cavity which would be transported via the synovial fluid and/or diffused to the chondrocytes or synoviocytes.
Export Options
About this article
Cite this article as:
Stove J., Lehmann L., Fickert S., Aigner T. and Brenner R., Artificial Organs: A New Option for Treating Osteoarthritis, Current Drug Delivery 2007; 4 (1) . https://dx.doi.org/10.2174/156720107779314839
DOI https://dx.doi.org/10.2174/156720107779314839 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Mechanisms of Enhanced Vasoconstriction in the Mouse Model of Atherosclerosis: the Beneficial Effects of Sildenafil
Current Pharmaceutical Biotechnology Gonadotropin-Releasing Hormone (GnRH) Receptors in Tumors: a New Rationale for the Therapeutical Application of GnRH Analogs in Cancer Patients?
Current Cancer Drug Targets Preparation and Characterization of Coaxial Electrospun Fibers Containing Triclosan for Comparative Study of Release Properties with Amoxicillin and Epicatechin
Current Drug Delivery MicroRNAs as Therapeutic Agents: The Future of the Battle Against Cancer
Current Topics in Medicinal Chemistry A New and Effective Approach to the Synthesis of Sulforaphane
Letters in Organic Chemistry Theranostic Radiopharmaceuticals Targeting Cancer-Associated Fibroblasts
Current Radiopharmaceuticals Targeting Receptor Tyrosine Kinases Using Monoclonal Antibodies: The Most Specific Tools for Targeted-Based Cancer Therapy
Current Drug Targets PET Designated Flouride-18 Production and Chemistry
Current Topics in Medicinal Chemistry Chemotherapy for Prostate Cancer
Current Pharmaceutical Design Radiolabeled Peptides and Proteins in Cancer Therapy
Protein & Peptide Letters Fiber-Optic Technologies in Laser-Based Therapeutics: Threads for a Cure
Current Pharmaceutical Biotechnology Stroke and Neuroinflamation: Role of Sexual Hormones
Current Pharmaceutical Design 5-HT<sub>6</sub> Receptor Antagonists: Potential Efficacy for the Treatment of Cognitive Impairment in Schizophrenia
Current Pharmaceutical Design Diffusion-Weighted MRI for Assessment of Early Cancer Treatment Response
Current Pharmaceutical Biotechnology Tissue Distribution of Glutamate Carboxypeptidase II (GCPII) with a Focus on the Central and Peripheral Nervous System
Current Medicinal Chemistry Targeting of Adhesion Molecules as a Therapeutic Strategy in Multiple Myeloma
Current Cancer Drug Targets Systems Biology of Apoptosis and Survival: Implications for Drug Development
Current Pharmaceutical Design Protein Microarrays: Technological Aspects, Applications and Intellectual Property
Recent Patents on Biotechnology Bioconversion of Isoflavones into Bioactive Equol: State of the Art
Recent Patents on Food, Nutrition & Agriculture The Role of Histone Demethylase GASC1 in Cancer and its Therapeutic Potential
Current Cancer Therapy Reviews